Tat-NR2Baa
| 中文名称 | Tat-NR2Baa |
|---|---|
| 中文同义词 | H-TYR-GLY-ARG-LYS-LYS-ARG-ARG-GLN-ARG-ARG-ARG-LYS-LEU-SER-SER-ILE-GLU-ALA-ASP-ALA-OH;TAT-NR2B9C对照多肽 |
| 英文名称 | Tat-NR2Baa |
| 英文同义词 | Tat-NR2Baa;L-Alanine, L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-leucyl-L-seryl-L-seryl-L-isoleucyl-L-α-glutamyl-L-alanyl-L-α-aspartyl- |
| CAS号 | 847829-41-8 |
| 分子式 | C103H184N42O29 |
| 分子量 | 2474.87 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 847829-41-8.mol |
| 结构式 |  |
Tat-NR2Baa 性质
| 密度 | 1.52±0.1 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
Tat-NR2BAA (125 ng; 20 mins) does not effects interactions between PSD-95 and NR2B subunits. In contrast, coimmunoprecipitation of PSD-95 with NR2B subunits is markedly decreased in rats pretreated with the disrupting peptide Tat-NR2B9c in lumbar dorsal horn tissue. Tat-NR2Baa (125 ng or 1.25 μg; 20 minutes before collection of lumbar dorsal horn tissue) is the control group of Tat-NR2B9c. Tat-NR2B9c produces a significant and robust reduction of postdischarge, indicating the hyperexcitability of the cell. But Tat-NR2Baa has no effects, even at a dose 100× greater than the active peptide Tat-NR2B9c (HY-P0117).Tat-NR2Baa (1 μM; pre-treatment 1 hour) is the control group in the Co-IP assay. Tat-NR2B9c (1 μM) disrupts NR2B/PSD95 interaction, and the coupling of NR2B to PSD-95 is more sensitive than NR2A/PSD95 to disruption in hippocampal neurons.
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/04/30 | HY-P2307 | Tat-NR2Baa Tat-NR2Baa | 847829-41-8 | 1mg | 2200元 |
| 2024/04/30 | HY-P2307 | Tat-NR2Baa Tat-NR2Baa | 847829-41-8 | 5mg | 5500元 |